What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?

AMA J Ethics. 2022 Nov 1;24(11):E1083-1090. doi: 10.1001/amajethics.2022.1083.


This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation for Economic Co-operation and Development member nations: the United Kingdom, Germany, and Canada. Specifically, this article compares these countries' policies on list and net price disclosures and on how international reference pricing is used to evaluate merits and drawbacks of different pricing transparency approaches. Finally, the article summarizes what policymakers in the United States should learn from these comparisons.

MeSH terms

  • Canada
  • Costs and Cost Analysis
  • Drug Costs*
  • Humans
  • Prescription Drugs*
  • United Kingdom
  • United States


  • Prescription Drugs